Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4

Conditions

Sarcoma, Kaposi 4Neoplasms 4HIV Infections 4Acquired Immunodeficiency Syndrome 4

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × tecogalan × Clear all
NCT00002136 2005-06-24

A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002137 2005-06-24

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002138 2005-06-24

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days.

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

NCT00002342 2005-06-24

A Study of Tecogalan Sodium

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
Sarcoma

Acquired Immunodeficiency Syndrome, Neoplasms, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡